Latest News

Henrique Oliva, MD, PhD, postdoctoral associate; Gustavo A. Angarita, MD, MHS, assistant professor of psychiatry, and Yale colleagues conducted comprehensive meta-analysis on spine density as it relates to substance use. The findings were published in Molecular Psychiatry.

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry and director of the Yale Depression Research Program, spoke to CNN about the use of ketamine to treat anxiety and depression.

Samuel Wilkinson, MD, associate professor of psychiatry, writes about achievement and maintaining relationships in Time.

Samuel T. Wilkinson, MD, associate professor of psychiatry, is author of the new book "Purpose: What Evolution And Human Nature Imply About the Meaning of Our Existence?"

Gerard Sanacora, MD, PhD (left), George D. and Esther S. Gross Professor of Psychiatry, and Samuel Wilkinson, MD, associate professor of psychiatry, have received $12.6 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for the study, “Comparative Effectiveness of Racemic Ketamine versus S-Ketamine (Spravato) for Depression.”

John Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology; and Irina Esterlis, PhD, associate professor of psychiatry, are first and senior authors, respectively, of a review published in Proceedings of the National Academy of Sciences Perspective that considers what scientists have learned from studies of ketamine and to suggest future directions for the optimization of rapid-acting antidepressant treatment.

Samuel Wilkinson, MD, associate professor of psychiatry, and Greg Rhee, PhD, assistant professor adjunct of psychiatry, have been awarded two grants through the National Institutes of Health Research Project Grants Program.

Sina Nikayin, MD, assistant professor of psychiatry, and Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, are co-authors of a viewpoint in JAMA Psychiatry that explores how expectations influence outcomes of psychedelic drug therapy.

Off-label, unsupervised use of ketamine has skyrocketed since regulatory changes were put in place at the height of the COVID pandemic. Yale psychiatrist Gerard Sanacora, a worldleader in ketamine research and clinical use, discusses some of the risks patients may be taking.